A case series of serious and unexpected adverse drug reactions under treatment with cariprazine
暂无分享,去创建一个
E. Rüther | G. Szycik | S. Bleich | C. Schroeder | I. Adamovic | R. Grohmann | S. Toto | D. Degner | D. Stichtenoth | Adrian Groh | J. Seifert | Michael Schneider | C. Glocker | J. Heck
[1] D. Copolov,et al. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia , 2020, CNS Drugs.
[2] S. Stahl,et al. Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data , 2020, Therapeutic advances in psychopharmacology.
[3] K. Demyttenaere,et al. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis , 2019, CNS Drugs.
[4] J. Malinovsky. An Introduction to Pharmacovigilance, 2nd ed , 2018, Anesthesia & Analgesia.
[5] M. Kołaczkowski,et al. The preclinical discovery and development of cariprazine for the treatment of schizophrenia , 2018, Expert opinion on drug discovery.
[6] A. Altamura,et al. Clinical Pharmacokinetics of Atypical Antipsychotics: An Update , 2018, Clinical Pharmacokinetics.
[7] N. Kanahara,et al. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice , 2017, Journal of psychopharmacology.
[8] Michael Diduch,et al. Review of cariprazine in management of psychiatric illness. , 2017, The mental health clinician.
[9] H. Nasrallah,et al. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis , 2017, BMC Psychiatry.
[10] P. Czobor,et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial , 2017, The Lancet.
[11] Ashley Tewksbury,et al. Management of antipsychotic-induced hyperprolactinemia , 2016, The mental health clinician.
[12] L. Citrome. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability , 2013, Expert opinion on drug metabolism & toxicology.
[13] J. López-Sendón,et al. Drug-Induced Parkinsonism in the Elderly , 2012, Drugs & Aging.
[14] O. Rascol,et al. Drug‐induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in France , 2011, Movement disorders : official journal of the Movement Disorder Society.
[15] Eva Schmidt,et al. Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist–Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile , 2010, Journal of Pharmacology and Experimental Therapeutics.
[16] P. Waller,et al. An Introduction to Pharmacovigilance , 2009 .
[17] J. Adán-Manes,et al. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis , 2009, Journal of clinical pharmacy and therapeutics.
[18] M. C. Catalano,et al. Acute akathisia associated with quetiapine use. , 2005, Psychosomatics.
[19] J. Williamson,et al. DRUG-INDUCED PARKINSONISM IN THE ELDERLY , 1984, The Lancet.
[20] Psychiatrischen Pharmakotherapie. Kompendium der Psychiatrischen Pharmakotherapie , 2019 .
[21] Ich Harmonised,et al. INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .
[22] S. Ramaswamy,et al. Aripiprazole possibly worsens psychosis. , 2004, International clinical psychopharmacology.